BioPharmX to Present Research at Vitafoods Europe Showing that Molecular Iodine is Key to the Healthy Aging of Women's Breasts
Company is one of a handful of presenters featured during the global conference
MENLO PARK, California, May 9, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the women's health and dermatology markets, will present research showing the link between molecular iodine and lifelong breast health in women.
Logo - http://photos.prnewswire.com/prnh/20150711/235327LOGO
The study, entitled "Molecular Iodine: the Missing Key to Healthy Aging of the Female Breast," is the only poster presentation on breast health at Vitafoods™ Europe Conference, an international meeting dedicated to ingredients and raw materials for the nutraceutical, functional food and drink and nutricosmetics industries.
"Our review of literature shows that adequate daily supplementation with molecular iodine yields protection against the development of fibrocystic tissue in breasts," said AnnaMarie Daniels, executive vice president of regulatory and clinical affairs, who will present the company's findings at Vitafoods Europe. "Studies have repeatedly shown that taking the right kind of molecular iodine supplements can significantly improve the quality of life for women."
The research, which reviews three studies involving more than 2,200 women, concludes that molecular iodine can help restore normal breast tissue and decrease the symptoms of an ailment known as fibrocystic breast condition (FBC), including breast swelling, pain and tenderness that can interfere with activities of daily life.
FBC affects at least 70 percent of premenopausal women. The condition occurs when repeated hormonal exposure accelerates cell division, often resulting in the formation of cysts, fibrous tissue and chronic inflammation.
BioPharmX has developed a novel and proprietary formulation of molecular iodine that delivers the optimal dose to alleviate FBC symptoms. The product, Violet® iodine, is commercially available in the United States. It is also the subject of a multicenter clinical trial in women with moderate to severe FBC to confirm the safety and expand claims.
Vitafoods screens proposals to present posters at its annual meeting. Event organizers describes the poster presentations as a "showcase [of] excellence in nutritional science, innovation, business and education."
The event is expected to attract 800 exhibitors and more than 15,600 visitors.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statement
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding, the success of the commercialization of VI2OLET iodine and the conclusion of its Phase 4 study of the company's Violet® molecular iodine supplement for fibrocystic breast condition (FBC) and cyclic mastalgia, which has been approved by an institutional review board in the U.S. and by Health Canada. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
BioPharmX and Violet are registered trademarks of BioPharmX, Inc. All other products or name brands are trademarks of their respective holders.
Share this article